The DBT said it has approved additional funding towards clinical studies of India’s first of its kind’ mRNA-based COVID-19 vaccine, HGCO19, developed by Pune-based biotechnology company Gennova Biopharmaceuticals Ltd.
Copyright © 2024 | WordPress Theme by MH Themes